Non-renounceable Entitlement Offer
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Percheron Therapeutics Limited has announced a non-renounceable entitlement offer to raise funds for its lead asset development and working capital needs. Eligible shareholders will be offered two new shares for every five existing shares held at a specified issue price, along with free attaching options. The offer is not underwritten and will close on a specified date, with further details provided in the accompanying prospectus.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Percheron Therapeutics Limited on 6ix
Earlier from Percheron Therapeutics
- Half Yearly Report and Accounts
- Quarterly Activities/Appendix 4C Cash Flow Report
- Quarterly Activities Report and Appendix 4C
- Percheron Therapeutics Limited to Present at the Life Sciences Virtual Investor Forum September 18th
- Appendix 4E and Annual Report
Later from Percheron Therapeutics
- Prospectus - Non-renounceable Entitlement Offer
- Results of Entitlement Offer
- Percheron Therapeutics Announces CEO Succession
- Vanderbilt Health to conduct clinical trial of HMBD-002
- Percheron raises $2.3m to fully fund clinical trial in AML
Follow Percheron Therapeutics into a list and get an email when it puts out news.
Follow Percheron Therapeutics